Use of biologics for psoriasis in Central and Eastern European countries

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F15%3A43910448" target="_blank" >RIV/00216208:11120/15:43910448 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/15:#0000501

Výsledek na webu

<a href="http://dx.doi.org/10.1111/jdv.13222" target="_blank" >http://dx.doi.org/10.1111/jdv.13222</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/jdv.13222" target="_blank" >10.1111/jdv.13222</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Use of biologics for psoriasis in Central and Eastern European countries

Popis výsledku v původním jazyce

ObjectivesTo evaluate the use of biological agents for the treatment of psoriasis and to explore country-specific differences within six Central and Eastern European (CEE) countries, namely Bulgaria, Croatia, the Czech Republic, Hungary, Poland and Romania. MethodsA literature overview on the epidemiology and disease burden of psoriasis in CEE was conducted. The number of patients treated with biologics was obtained from patient registries, ministries of health, national professional societies and health insurance funds. Biological treatment rates were estimated by two different methods: (i) as a proportion of all psoriasis patients of a country (assuming a common prevalence of psoriasis 2%) and (ii) per 100000 population. Moreover, we provide a detailed comparison of drug coverage policies and guidelines regulating the treatment with biologics in psoriasis. ResultsOn average 0.25% of all psoriasis patients, or five psoriasis patients out of 100000 inhabitants are treated with biologic

Název v anglickém jazyce

Use of biologics for psoriasis in Central and Eastern European countries

Popis výsledku anglicky

ObjectivesTo evaluate the use of biological agents for the treatment of psoriasis and to explore country-specific differences within six Central and Eastern European (CEE) countries, namely Bulgaria, Croatia, the Czech Republic, Hungary, Poland and Romania. MethodsA literature overview on the epidemiology and disease burden of psoriasis in CEE was conducted. The number of patients treated with biologics was obtained from patient registries, ministries of health, national professional societies and health insurance funds. Biological treatment rates were estimated by two different methods: (i) as a proportion of all psoriasis patients of a country (assuming a common prevalence of psoriasis 2%) and (ii) per 100000 population. Moreover, we provide a detailed comparison of drug coverage policies and guidelines regulating the treatment with biologics in psoriasis. ResultsOn average 0.25% of all psoriasis patients, or five psoriasis patients out of 100000 inhabitants are treated with biologic

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FO - Dermatovenerologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of the European Academy of Dermatology and Venereology

ISSN

0926-9959

e-ISSN

—

Svazek periodika

29

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

2222-2230

Kód UT WoS článku

000363983000021

EID výsledku v databázi Scopus

—